To include your compound in the COVID-19 Resource Center, submit it here.

Zai: Capitalizing on China

Zai in-licensing Western compounds targeting diseases prevalent in China

Zai Laboratory Inc. is looking to in-license and develop a pipeline of novel compounds that target diseases prevalent in China and greater Asia and that also will have a global market. Zai's first deal came last month when it received worldwide rights to a pair of undisclosed pulmonary compounds from Sanofi.

The company and its investors believe the Chinese market is large enough to support multiple players pursuing the in-licensing model. Zai's investors also believe the newco's management team has the experience and

Read the full 825 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers